For nearly two decades, Melodia has operated in silence; behind NDAs, closed doors and hushed referrals. But now, in 2025, she’s ready to step forward and share what she’s been doing all along: ...
Unique programmability lets you re-create a professional audiogram in the app. Quite comfortable despite large size. Excellent as streaming receivers. Moderate trouble with overall level and echoes in ...
BASEL, Switzerland, Sept. 2, 2025 /PRNewswire/ -- Melodia Therapeutics, a Forty51 Ventures company, developing a next generation DPP1 inhibitor with best-in-class potential for inflammatory conditions ...
TOKYO--(BUSINESS WIRE)--Alivexis, Inc. (headquartered in Tokyo, Japan, “Alivexis”) and Melodia Therapeutics AG (headquartered in Basel, Switzerland, “Melodia”), a company established by Forty51 ...
BASEL, Switzerland, Feb. 25, 2026 /PRNewswire/ -- Melodia Therapeutics AG today announced that the United States Patent and Trademark Office (USPTO) has granted a key U.S. patent covering a ...
Alivexis, Inc. and Melodia Therapeutics AG, a company established by Forty51 Ventures, announced that they have entered into an exclusive license agreement for the worldwide development, manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results